Generic drug company Teva Pharmaceutical Industries Ltd. Oct. 14 announced it has completed its acquisition of Cephalon Inc. for approximately $6.8 billion.
Teva announced its plans to acquire Cephalon in May. Recently, the Federal Trade Commission said it would allow Teva to complete the acquisition, as long as Teva first sold its rights to the generic version of the cancer pain drug Actiq (transmucosal fentanyl citrate lozenges) and the branded muscle relaxant Amrix (extended release cyclobenzaprine hydrochloride) (9 PLIR 1286, 10/14/11).
“This important transaction reinforces Teva’s long term strategy of building out our branded and specialty pharmaceuticals business ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.